Fig 4.

Comparative effectiveness of GLP-1 receptor agonists versus DPP-4 inhibitors for primary outcome of risk of hyperkalemia diagnosis in inpatient or outpatient setting among subgroups after 1:1 propensity score matching. Number of propensity score matched patients in subgroups do not exactly add up to overall number of propensity score matched patients in main analysis because propensity score matching was performed within each subgroup; therefore, it is possible that more patients are matched within subgroups. ACE=angiotensin converting enzyme inhibitor; ARB=angiotensin II receptor blocker; ARNI=angiotensin receptor/neprilysin inhibitor; CI=confidence interval; CVD=cardiovascular disease; CKD=chronic kidney disease; DPP-4=dipeptidyl peptidase-4; GLP-1=glucagon-like peptide-1; IR=incidence rate; MRA=mineralocorticoid receptor antagonist; PY=person years. *Only data from Medicare; †only data from Optum’s deidentified Clinformatics Data Mart Database